| Unique ID issued by UMIN | UMIN000006964 |
|---|---|
| Receipt number | R000008223 |
| Scientific Title | Examination for the effect of combination therapy with alendronate and eldecalcitol in primary osteoporotic patients :A randomized active comparator study -Switch from alfacalcidol to eldecalcitol- |
| Date of disclosure of the study information | 2011/12/27 |
| Last modified on | 2021/01/02 09:35:40 |
Examination for the effect of combination therapy with alendronate and eldecalcitol in primary osteoporotic patients :A randomized active comparator study
-Switch from alfacalcidol to eldecalcitol-
Examination for the effect of combination therapy with alendronate and eldecalcitol for osteoporosis -Switch from alfacalcidol to eldecalcitol-
Examination for the effect of combination therapy with alendronate and eldecalcitol in primary osteoporotic patients :A randomized active comparator study
-Switch from alfacalcidol to eldecalcitol-
Examination for the effect of combination therapy with alendronate and eldecalcitol for osteoporosis -Switch from alfacalcidol to eldecalcitol-
| Japan |
Osteoporosis
| Endocrinology and Metabolism | Geriatrics | Obstetrics and Gynecology |
| Orthopedics |
Others
NO
To examine the BMD increase at lumbar spine in primary osteoporotic patients who had taken combination therapy with alendronate and alfacalcidol by switching from alfacalcidol to eldecalcitol.
Safety,Efficacy
Change of lumbar spine bone mineral density
Change of total hip bone mineral density
Number of fracture occurred
Change of bone metabolic markers
Safety
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
NO
NO
Institution is not considered as adjustment factor.
NO
Central registration
2
Treatment
| Medicine |
Alendronate (35mg/week) + alfacalcidol (1.0ug/day) for 48 weeks
Alendronate (35mg/week) + eldecalcitol (0.75ug/day) for 48 weeks
| 20 | years-old | <= |
| Not applicable |
Male and Female
(1) Primary osteoporotic patients
(2) Patients who are treated with alendronate and alfacalcidol for more than 24 weeks and less than five years
(3) Patients with informed of consent
(1) Patients who are diagnosed as contraindication of alendronate treatments
(2) Patients who are diagnosed as contraindication of eldecalcitol treatments
(3) Patients who are treated with glucocorticoid
(4) Patients who have serum calcium levels of above 10.5mg/dL
(5) Patients who have taken osteoporosis treatments other than alendronate and alfacalcidol
(6) Patients who are inappropriate for this study by physician
120
| 1st name | |
| Middle name | |
| Last name | Junji Chiba |
Tokyo Women's Medical University Medical Center East
Department of Orthopaedic Surgery
2-1-10 Nishiogu, Arakawa, Tokyo, Japan
03-3810-1111
| 1st name | |
| Middle name | |
| Last name | Yasuo Inoue |
Tokyo Women's Medical University Medical Center East
Department of Orthopaedic Surgery
2-1-10 Nishiogu, Arakawa, Tokyo, Japan
03-3810-1111
i-yasuo2@apr.so-net.jp
Tokyo Women's Medical University Medical Center East
None
Self funding
NO
| 2011 | Year | 12 | Month | 27 | Day |
Unpublished
Completed
| 2011 | Year | 12 | Month | 26 | Day |
| 2011 | Year | 11 | Month | 13 | Day |
| 2012 | Year | 01 | Month | 01 | Day |
| 2014 | Year | 01 | Month | 01 | Day |
| 2011 | Year | 12 | Month | 27 | Day |
| 2021 | Year | 01 | Month | 02 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008223